



For immediate release 7.00am: 6 January 2016

HVIVO PLC
(“hVIVO” or the “Company”)

Directors’ Dealings

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, announces that application has been made to AIM for the admission of 7,520 new ordinary shares of 5.0p each in the Company (the “New Ordinary Shares”).

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company’s announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase \$20,000 and £4,000 of hVIVO plc new ordinary shares respectively per quarter. The New Ordinary Shares represent their investments for the quarter ended 31 December 2015. On 5 January 2016, Mr Ellertson invested in an additional 5,797 ordinary shares and Mr Winschel invested in an additional 1,723 ordinary shares.

Following admission of the 7,520 New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,060,304 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.

Admission of the New Ordinary Shares (“Admission”), which will rank pari passu in all respects with the Company’s existing shares in issue, is expected to occur on 11 January 2016. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 30,962 and 28,136 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company’s issued share capital.

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases.

Through its illumination of the entire disease life cycle from healthy to sick and back to health, the hVIVO platform captures disease in motion and promotes rational selection of drug targets and biomarkers in respiratory and infectious diseases, such as flu and colds. It brings together a revolutionary set of capabilities in product validation testing and the mining of biological insights, in order to tackle the long timeline, significant costs and high risks to market facing drug development and diagnostic organisations today.

A market leader in human disease models and challenge studies, hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academia clients and collaborators.